Intravesical mitomycin-C administered immediately before transurethral resection of bladder tumor in non-muscle-invasive bladder cancer: Clinical outcomes and molecular predictors from over 3 years of extended follow-up in a phase II trial.
Investig Clin UrolSep 1, 2026
Hye Won Lee, Geehyun Song, Hyung Ho Lee et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase II randomized controlled trial evaluated the long-term outcomes of immediate preoperative intravesical chemotherapy with mitomycin-C (MMC) in 71 patients with non-muscle-invasive bladder cancer (NMIBC). The study found that MMC reduced recurrence risk by 76.8% compared to transurethral resection alone, with a 3-year recurrence-free survival rate of 90.7% versus 78.6%.
Key findings
- IPeIC/MMC reduced recurrence risk by 76.8% compared to TURBT alone (p=0.024).
- 3-year recurrence-free survival rate was 90.7% for IPeIC/MMC versus 78.6% for controls.
- IPeIC was associated with 100% progression-free survival at 3 years compared to 92.1% in controls (HR 0.078, p=0.014).
- Low GSTM1 expression was identified as a strong predictor of recurrence.
Why it matters
The findings suggest that immediate preoperative intravesical chemotherapy with MMC can significantly improve long-term outcomes in NMIBC patients, offering a potential alternative for those unable to receive standard postoperative treatments.